Skip to main content

Advertisement

SpringerLink
Log in

Clinical trials

A revolution in obesity treatment

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Mounting evidence, including the recent (and unprecedented) phase 2 data on retatrutide, supports a role for incretin hormone agonists in treating obesity. But with great power comes great responsibility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Weight loss with second-generation obesity pharmacotherapies.

References

  1. Jastreboff, A. M. et al. N. Engl. J. Med. 389, 514–526 (2023).

    Article  CAS  PubMed  Google Scholar 

  2. Rosenstock, J. et al. Lancet 402, S0140–6736 (2023).

    Article  PubMed  Google Scholar 

  3. Nogueiras, R., Nauck, M. A. & Tschöp, M. H. Nat. Metab. 5, 933–944 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Wilding, J. P. H. et al. N. Engl. J. Med. 384, 989–1002 (2021).

    Article  CAS  PubMed  Google Scholar 

  5. Davies, M. et al. Lancet 397, 971–984 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Jastreboff, A. M. et al. N. Engl. J. Med. 387, 205–216 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Garvey, W. T. et al. Lancet 402, 613–626 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Le Roux, C. Diabetes https://doi.org/10.2337/db23-51-OR (2023).

    Article  Google Scholar 

  9. Wharton, S. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2302392 (2023).

    Article  PubMed  Google Scholar 

  10. Knop, F. K. et al. Lancet 402, 705–719 (2023).

    Article  CAS  PubMed  Google Scholar 

  11. Saxena, A. R. et al. JAMA Netw. Open. 6, e2314493 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Aroda, V. R. et al. Lancet 402, 693–704 (2023).

    Article  CAS  PubMed  Google Scholar 

  13. Frias, J. P. et al. Lancet 402, 720–730 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ildiko Lingvay & Shubham Agarwal

  2. Peter O’Donnell Jr School of Public Health, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ildiko Lingvay

Authors
  1. Ildiko Lingvay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shubham Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ildiko Lingvay.

Ethics declarations

Competing interests

I.L. received grants paid to the Institution from Novo Nordisk, Pfizer, Merck, Sanofi, Boehringer Ingelheim and Mylan; and received consulting fees and covered travel expenses from Novo Nordisk, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Sanofi, Boehringer Ingelheim, Zealand, Bayer, Intercept, Valeritas, Structure, Carmot, Shionoghi, Mediflix and WebMD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lingvay, I., Agarwal, S. A revolution in obesity treatment. Nat Med 29, 2406–2408 (2023). https://doi.org/10.1038/s41591-023-02538-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02538-7

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation